Antibiotic Resistance and Acne: Where We Stand and What the Future Holds

June 2014 | Volume 13 | Issue 6 | Supplement Individual Articles | 66 | Copyright © June 2014


Whitney P. Bowe MD

SUNY Downstate College of Medicine, Brooklyn, NY

table 2
severe AV.9 A total of 459 subjects were randomized in a 1:1 ratio to receive for 12 weeks oral doxycycline once daily or either Epiduo or a vehicle gel once daily. The efficacy of doxycycline and Epiduo was demonstrated by week 2 compared with the vehicle arm for total inflammatory and noninflammatory lesions.9 By week 12, the doxycycline and Epiduo group was superior to vehicle in reducing total inflammatory and noninflammatory lesion counts and for global success and overall participant satisfaction. 9 Digital UV fluorescence photography also showed an expeditious and efficacious reduction to P. acnes in the doxycycline and Epiduo group (Figure 3).9
Whereas ACCESS I focused on the primary treatment of acne with Epiduo, ACCESS II evaluated the safety and efficacy of Epiduo for maintenance therapy or relapse prevention.10 ACCESS II was a 24-week, multicenter, double-blind, randomized extension of ACCESS I that compared Epiduo with vehicle in 243 subjects. After the randomized subjects were treated for 12 weeks in ACCESS I, and had experienced at least a 50% global improvement in their AV, they were randomized to receive Epiduo gel or its vehicle once daily for 24 weeks.10 By week 24, when Epiduo was compared with vehicle, it yielded a significantly higher lesion maintenance success rate for all lesions; and a significantly greater number of subjects who had been administered Epiduo had an equivalent or superior Investigator’s Global Assessment score at week 24 than at baseline.10 In ACCESS II, Epiduo resulted in further decrease of lesion counts, and 45.7% of subjects were “clear” or “almost clear” at week 24 (Figure 4).10,11
Leyden et al evaluated the effectiveness of adapalene and BPO combination gel in the reduction of antibiotic-sensitive and resistant strains of P. acnes on the facial skin. This 4-week, open-label, single-center study included 30 healthy adults with high facial P. acnes populations that were resistant to one or more of the following antibiotics: erythromycin, tetracycline, clindamycin, minocycline, and doxycycline.12 Although all of the subjects had P. acnes strains resistant to one or more of the 5 antibiotics at baseline, the total P. acnes counts decreased by 1.1 logs after 2 weeks of treatment and by 1.6 logs after 4 weeks.12 In addition to reducing population densities of P. acnes, adapalene and BPO combination gel completely eradicated antibiotic resistant strains in some subjects.12